pf-06835919
Small moleculeexperimental
Clinical trial activity
7 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2016 (NCT02974374)
Timeline
Indications
Mechanism of action
- KetohexokinaseINHIBITOR
KHK inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
C[C@H]1CCN1c1nc(N2C[C@@H]3[C@@H](CC(=O)O)[C@@H]3C2)cc(C(F)(F)F)n1- Mol. weight
- 356.35 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4549658 ↗
Also known as
- pf-06835919
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04427917 | Phase 1 | Jul 22, 2020 | Pfizer |
| NCT04193436 | Phase 1 | Jan 21, 2020 | Pfizer |
| NCT03969719 | Phase 2 | Jul 18, 2019 | Pfizer |
| NCT03916406 | Phase 1 | Apr 18, 2019 | Pfizer |
| NCT03256526 | Phase 2 | Sep 27, 2017 | Pfizer |
| NCT03031119 | Phase 1 | Jan 1, 2017 | Pfizer |
| NCT02974374 | Phase 1 | Oct 1, 2016 | Pfizer |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Pfizer | For profit | 7 | 7 | 2 | 2016 |
1 organizations
Page 1 / 1